解码瘤血管生成:抗癌策略中的途径,机制和未来方向
Xueru Liu1, Juan Zhang1, Ting Yi2
1Department of Assisted Reproductive Centre, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, 412000, Hunan, China.
Biomarker research
|April 18, 2025
概括
本综述探讨了癌症的抗血管生成策略,重点关注分子机制和治疗点. 它强调了诸如耐药性等挑战,并讨论了未来抗血管生成疗法的方向.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管新生对于瘤生长和转移至关重要.
- 针对性抗血管生成疗法对于癌症治疗至关重要.
- 了解瘤微环境和内皮细胞代谢是关键.
研究的目的:
- 审查关于瘤中抗血管生成标的最新知识.
- 分析调节瘤血管生成的分子机制和信号通路.
- 评估治疗策略和抗血管生成药物开发的未来趋势.
主要方法:
- 对抗血管生成研究的综合文献综述.
- 对分子机制和信号通路的分析.
- 评估治疗策略和药物开发趋势.
主要成果:
- 详细分析瘤血管生成的信号通路和分子机制.
- 在瘤微环境中识别关键的分子标.
- 评估针对瘤血管的当前和新兴治疗策略.
结论:
- 抗血管生成疗法显示出希望,但面临着药物耐药性和副作用等挑战.
- 需要进行持续的研究,以改善癌症治疗策略和治疗疗效.
- 未来的方向包括开发新药和克服治疗耐药性.
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.